S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon

SAB Biotherapeutics (SABS) Earnings Date, Estimates & Call Transcripts

$4.29
-0.17 (-3.81%)
(As of 04/19/2024 ET)
Skip Charts & View Estimated and Actual Earnings Data

SABS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SABS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

SAB Biotherapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.98)($0.98)($0.98)
Q2 20241($1.14)($1.14)($1.14)
Q3 20241($1.28)($1.28)($1.28)
Q4 20241($1.49)($1.49)($1.49)
FY 20244($4.89)($4.89)($4.89)

SABS Earnings Date and Information

SAB Biotherapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 21st, 2024 based off prior year's report dates.

SAB Biotherapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/21/2024
Estimated)
------- 
11/13/2023Q3 2023($0.10)($0.10)-($0.10)-$1.27 million
8/21/2023Q2 2023($0.14)($0.14)-($0.14)-$0.09 million
5/16/2023Q1 2023($0.08)($0.15)($0.07)($0.15)$5.56 million$0.58 million
11/15/2022Q3 2022($0.14)($0.16)($0.02)($0.16)-$3.59 million
8/10/2022Q2 2022($0.13)($0.11)+$0.02($0.11)$14.40 million$6.35 million
5/12/2022Q1 2022($0.12)($0.15)($0.03)($0.32)$13.20 million$11.80 million
11/22/2021Q3 2021($0.06)($0.02)+$0.04($0.02)--

SAB Biotherapeutics Earnings - Frequently Asked Questions

When is SAB Biotherapeutics's earnings date?

SAB Biotherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 21st, 2024 based off last year's report dates. Learn more on SABS's earnings history.

How much revenue does SAB Biotherapeutics generate each year?

SAB Biotherapeutics (NASDAQ:SABS) has a recorded annual revenue of $2.24 million.

How much profit does SAB Biotherapeutics generate each year?

SAB Biotherapeutics (NASDAQ:SABS) has a recorded net income of -$42.19 million. SABS has generated $0.00 earnings per share over the last four quarters.

What is SAB Biotherapeutics's EPS forecast for next year?

SAB Biotherapeutics's earnings are expected to decrease from ($4.31) per share to ($6.21) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:SABS) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners